Essential Drugs Price Hike: Iran War Impact Pushes Costs Up 5 Percent

The essential drugs price hike due to Iran war is starting to reflect in India’s pharmaceutical market, with reports indicating that prices of key medicines may rise by up to 5 percent in the near term.  

The increase is being linked to ongoing geopolitical tensions in the Middle East, which are disrupting trade routes and pushing up global logistics costs. 

Shipping delays and higher freight charges are among the first visible effects. Key routes passing through the Strait of Hormuz have become more uncertain, leading to increased insurance and transportation expenses for exporters and importers. These added costs are gradually moving through the supply chain. 

Also Read: AbbVie Combo Trial Shows 62 Percent Response in Ovarian Cancer

The impact is also being felt in raw material sourcing. Active pharmaceutical ingredients, which form the core of drug manufacturing, are seeing price pressure due to delayed shipments and tighter global supply. This is adding strain on Indian drug manufacturers who depend heavily on imports for production. 

India’s pharmaceutical industry is deeply connected to global supply networks, especially for bulk drugs and intermediates sourced from Asia. Because of this dependency, even short-term disruptions in international trade quickly raise production costs and affect pricing decisions in the domestic market. 

The essential drugs price hike due to Iran war is still being described as limited and manageable. Industry experts say there are no immediate concerns about shortages, and supply chains are continuing to function.  

However, they also caution that if tensions persist or expand further, cost pressures could intensify and lead to broader price adjustments across essential medicines in the coming months.